Verona Pharma PLC
VRNA106.430USD
+0.030+0.03%
Fechamento 09/12, 16:00（ET）Cotações atrasadas em 15 min
73.22BValor de mercado
PerdaP/L TTM
Mais detalhes de Verona Pharma PLC Empresa
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Informações da empresa
Código da empresaVRNA
Nome da EmpresaVerona Pharma PLC
Data de listagemMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Número de funcionários209
Tipo de títulosDepository Receipt
Fim do ano fiscalMar 30
EndereçoRiverside
CidadeLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Telefone442032834200
Sitehttps://www.veronapharma.com/
Código da empresaVRNA
Data de listagemMar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
175.14K
-66.98%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
61.24K
-90.96%
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
14.74K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
11.76K
-84.20%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
11.68K
-84.01%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
10.61K
-84.92%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
1.59K
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
175.14K
-66.98%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
61.24K
-90.96%
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
14.74K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
11.76K
-84.20%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
11.68K
-84.01%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
10.61K
-84.92%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
7.12%
Perceptive Advisors LLC
6.39%
Darwin Global Management Ltd
4.79%
Frazier Life Sciences Management, L.P.
3.93%
Ali (Behbahani)
3.70%
Outro
74.07%
Investidores
Investidores
Proporção
Janus Henderson Investors
7.12%
Perceptive Advisors LLC
6.39%
Darwin Global Management Ltd
4.79%
Frazier Life Sciences Management, L.P.
3.93%
Ali (Behbahani)
3.70%
Outro
74.07%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
26.68%
Hedge Fund
26.24%
Investment Advisor
17.32%
Private Equity
10.42%
Venture Capital
4.96%
Individual Investor
4.89%
Research Firm
4.38%
Family Office
1.17%
Pension Fund
0.15%
Outro
3.79%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
423
82.86M
96.18%
-3.71M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
5.52M
6.48%
+3.85M
+230.91%
Mar 31, 2025
Perceptive Advisors LLC
6.56M
7.71%
+171.23K
+2.68%
Mar 31, 2025
Darwin Global Management Ltd
3.92M
4.61%
+3.11M
+384.08%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.46M
4.06%
+73.90K
+2.18%
Mar 31, 2025
Ali (Behbahani)
3.19M
3.75%
+3.19M
--
Jan 16, 2025
RTW Investments L.P.
2.85M
3.35%
+1.03M
+56.44%
Mar 31, 2025
Eventide Asset Management, LLC
2.89M
3.4%
-238.69K
-7.62%
Mar 31, 2025
New Enterprise Associates (NEA)
2.69M
3.16%
-1.40M
-34.18%
Mar 31, 2025
Summit Partners Public Asset Management, LLC
2.32M
2.73%
+421.09K
+22.14%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
AltShares Merger Arbitrage ETF
4.25%
First Trust International Equity Opportunities ETF
2.06%
iShares Biotechnology ETF
0.5%
Fidelity Nasdaq Composite Index ETF
0.03%
AltShares Merger Arbitrage ETF
Proporção4.25%
First Trust International Equity Opportunities ETF
Proporção2.06%
iShares Biotechnology ETF
Proporção0.5%
Fidelity Nasdaq Composite Index ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
